BioSpace News Archive

Verismo Therapeutics today announced that an abstract has been accepted for poster presentation at the upcoming American Association for Cancer Research Annual Meeting 2024 (AACR 2024), to be held in San Diego on April 5-10, 2024.

Purdue Pharma L.P. (“Purdue”) announced today that FDA has accepted for filing the company’s New Drug Application (NDA) for the auto-injector delivery form of nalmefene hydrochloride injection*.

Inozyme Pharma, Inc. announced positive topline safety, pharmacokinetic, pharmacodynamic and exploratory efficacy data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency.

Kymera Therapeutics, Inc. today announced that new preclinical data showing the structural and molecular mechanisms underlying anti-tumor activity of its novel STAT3 degrader, KT-333, were presented in a late-breaking research poster session at the AACR Annual Meeting taking place April 5-10, 2024, in San Diego, California.

XORTX Therapeutics Inc. announces that Dr. Allen Davidoff, CEO, is scheduled to participate in the following Spring 2024 investor and life sciences investment conferences.

Eyenovia, Inc., a commercial-stage ophthalmic company, announced its plans for accelerating development of its potential multi-billion dollar product for pediatric progressive myopia and initiated a process to explore strategic alternatives to maximize shareholder value.

Bruker Corporation announces novel magnet technology and analytical solutions to support broad adoption of NMR in academic basic and clinical research, as well as in biopharma drug discovery, development and process analytical technologies.

Shorla Oncology announced that the U.S. Food and Drug Administration has accepted for review the company’s New Drug Application for SH-201, the first palatable oral liquid of the related chemotherapeutic agent to treat certain forms of leukemia and other cancers.

Satellos Bioscience Inc. announced that management will present at and participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place April 16th and 17th in Toronto.

BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced a collaboration with Galen Patient Recruitment, Inc.